{
  "id": 7399160,
  "title": "Elicio Therapeutics at H.C. Wainwright: pivot to metastatic cancer",
  "url": "https://urgent.news/2026/09/14/elicio-therapeutics-at-h-c-wainwright-pivot-to-metastatic-cancer",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T21:21:17.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/elicio-therapeutics-at-hc-wainwright-pivot-to-metastatic-cancer-93CH-4900572"
  },
  "original_language": "en",
  "account": "On 14 September 2026, Elicio Therapeutics (ELTX) addressed investors at the H.C. Wainwright 28th Annual Global Investment Conference, delivering a mixed update on its progress. While early clinical signals remained promising, the company's lead randomized study, ELI-002, fell short of its primary goal. The company is now focusing on metastatic pancreatic cancer, a larger market with a faster path to later-stage testing. Chief Scientific Officer Pete DeMuth detailed the company's lymph node-targeted immunotherapy strategy and the latest KRAS-focused ELI-002 program data. Shares of ELTX closed at $2, down 2.44% from the previous close of $2.05, trading near its 52-week low of $2.02 and down 87.5% from its 52-week high of $16. The stock was unchanged in after-hours trading at $2. Elicio's Fair Value analysis suggests the stock may be slightly undervalued, but investors should note the company's weak overall financial health. The company plans to begin a Phase I metastatic pancreatic cancer trial in Q4 2024, with expected data in Q1 and Q2 2025.",
  "summary": null,
  "key_points": [
    "Elicio Therapeutics reports mixed results at H.C. Wainwright conference",
    "Lead study ELI-002 fails to meet primary goal",
    "Company pivots focus to metastatic pancreatic cancer"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}